Site menu

Search by ticker code:
Generic filters


Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Is It Time To Put CSL Limited (ASX:CSL) Shares On Your Watchlist?

CSL Limited (ASX: CSL) shares fell 3% Wednesday morning despite the biopharmaceutical giant hosting its research & development (R&D) investor update.

Indeed, it seems CSL shares have been caught up in a broad market sell-off despite delivering another promising operational and market update.

Who is CSL?

CSL is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900’s as the Commonwealth Serum Labratories , CSL was sold by the Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition.

Today, CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.

What’s Going On?

CSL hosts its research & development investor briefing today.

CSL spends between 10% and 11% of its yearly revenue on the research and development of new drugs and vaccines. According to today’s update, CSL has nine products in Phase III trials.

Big Opportunity

Commenting on the market opportunity, CSL’s Chief Commercial Officer Bill Campbell provided an overview of the market for CSL and where it fits.

Source: CSL Investor Update, Dec’ 2018

In 2018, CSL earned almost half ($3.14 billion) of its revenue from its immunoglobulin products, as can be seen above. Immunoglobulins are another way of saying antibodies.

In the past 12 months, CSL has launched privigen and Hizentra. These products are approved for use in 80 countries and 57 countries, respectively, and appear to be showing good early signs.

Source: CSL Investor Update, Dec’ 2018

As can be seen in the chart above, CSL’s target market is huge. So despite already growing at an enviable pace over decades, it seems CSL could be expected to experience further growth over the long run.

Time to Put CSL Shares on Your Watchlist?

With a proven track record, industry-leading products and more in the pipeline, CSL should be on Australian investors’ watchlists.

Having said that, I don’t own CSL shares because I haven’t done enough work on its products to understand the opportunity, the risks and arrive at a reasonable valuation.

Fortunately for me there are plenty of other great ASX shares offering both dividends and growth…

[ls_content_block id=”14945″ para=”paragraphs”]

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content